Invitation to BC TALKS - For hcp attending ESMO

Practical considerations when treating HR+, HER2-mBC patients: Impact of OS data on treatment choices, how do medical experts reason?

Join us LIVE on Sunday the 11th for an interactive session with breast cancer experts Dr. Caroline Duhem and Dr. Peter Fasching. Engage in LIVE discussions focusing on treatment for patients with HR+, HER2- mBC breast cancer.


  • OS vs. PFS as endpoints: clinical consideration and practical implications
  • Overall survival data with CDK4/6 inhibitors
  • Pharmakokinetic differences
  • How will the OS data affect the treatment landscape

If you have any questions or would like to sign up, please reach out to
Anita Fredriksen +47 40853299, [email protected]
Kind Regards,
Novartis Oncology


Medical Information Request


Ask Speakers